Microbiotica announced positive Phase Ib results for MB‑310, an orally administered live biotherapeutic for ulcerative colitis. In the randomized study, 12 of 19 treated patients achieved clinical remission versus 3 of 10 in the placebo arm; responders sustained remission through a three‑month follow‑up and showed improvements in histologic markers. Company executives presented the data as proof‑of‑concept for MB‑310’s ability to modulate mucosal inflammation and support clinical benefit. The readout supports further development and potential advancement into larger trials in inflammatory bowel disease. Source: Microbiotica phase Ib dataset and corporate presentation.